Nkarta Inc Asset Resilience Ratio
Nkarta Inc asset resilience ratio. Nkarta Inc (NKTX) has an Asset Resilience Ratio of 46.74% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Nkarta Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Nkarta Inc (2018–2025)
Asset resilience ratio of Nkarta Inc from 2018 to 2025. This chart shows how Nkarta Inc's Asset Resilience Ratio has changed over time. Read Nkarta Inc (NKTX) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Nkarta Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Nkarta Inc (NKTX) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $157.81 Million | 46.74% |
| Total Liquid Assets | $157.81 Million | 46.74% |
Asset Resilience Insights
- Very High Liquidity: Nkarta Inc maintains exceptional liquid asset reserves at 46.74% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Nkarta Inc Industry Peers by Asset Resilience Ratio
Compare Nkarta Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Nkarta Inc Asset Resilience Ratio by Year (2018–2025)
Nkarta Inc asset resilience ratio by year from 2018 to 2025. The table below shows the annual Asset Resilience Ratio data for Nkarta Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 58.55% | $236.65 Million | $404.21 Million | +10.76pp |
| 2024-12-31 | 47.78% | $239.48 Million | $501.20 Million | -9.53pp |
| 2023-12-31 | 57.31% | $217.15 Million | $378.88 Million | -9.22pp |
| 2022-12-31 | 66.53% | $314.65 Million | $472.94 Million | +1.81pp |
| 2021-12-31 | 64.72% | $177.27 Million | $273.90 Million | +0.09pp |
| 2020-12-31 | 64.63% | $218.22 Million | $337.65 Million | +30.79pp |
| 2019-12-31 | 33.84% | $16.38 Million | $48.41 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $9.61 Million | -- |
About Nkarta Inc
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myo… Read more